Inhibrx EV / EBITDA
Cos'è EV / EBITDA di Inhibrx?
EV / EBITDA di Inhibrx, Inc. è N/A
Qual è la definizione di EV / EBITDA?
EV / EBITDA è il valore aziendale diviso per guadagni prima di interessi, tasse, deprezzamento e ammortamento. È una misura di quanto sia costosa una azione ed è più frequentemente valida per i confronti tra le aziende rispetto al rapporto prezzo / guadagno. Misura il prezzo (sotto forma di valore d'impresa) che un investitore paga a vantaggio del flusso di cassa della società (sotto forma di EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA di aziende nel Health Care settore su NASDAQ rispetto a Inhibrx
Cosa fa Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Aziende con ev / ebitda simili a Inhibrx
- Wishpond Technologies ha EV / EBITDA di N/A
- Future Bright ha EV / EBITDA di N/A
- GoldQuest Mining ha EV / EBITDA di N/A
- Powercell Sweden Sk ,022 ha EV / EBITDA di N/A
- O3 Mining ha EV / EBITDA di N/A
- Tijaria Polypipes ha EV / EBITDA di N/A
- Inhibrx ha EV / EBITDA di N/A
- Kidsland International ha EV / EBITDA di N/A
- Americas Car Mart ha EV / EBITDA di N/A
- Reabold Resources Plc ha EV / EBITDA di N/A
- Ausmex Mining ha EV / EBITDA di N/A
- amalphi ag ha EV / EBITDA di N/A
- Silver Range Resources ha EV / EBITDA di N/A